Seek Returns

MRK vs. NVS: Merck vs. Novartis Stock Comparison

How do Merck (MRK) and Novartis (NVS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Merck (MRK) and Novartis (NVS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Merck (MRK) trades as ordinary local shares, while Novartis (NVS) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Merck (MRK) and Novartis (NVS)
Profile ItemMRKNVS
NameMerck & Co., Inc.Novartis AG Sponsored ADR
Country/RegionUnited StatesSwitzerland
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization364.26 billion USD303.12 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateJanuary 2, 1962November 7, 1996
Security TypeCommon StockADR

Price Performance

Cumulative Growth

MRK
NVS
GSPC
Loading price history…
Merck (MRK) vs. Novartis (NVS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Merck (MRK) and Novartis (NVS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Merck (MRK) and Novartis (NVS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Merck (MRK) and Novartis (NVS)
MetricMRKNVS
Total Return (1Y)63.67%25.38%
Total Return (3Y, Annualized)16.47%23.68%
Total Return (5Y, Annualized)15.44%18.60%

Risk Profile

Drawdown History

MRK
NVS
GSPC
Loading price history…
Merck (MRK) vs. Novartis (NVS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Merck (MRK) and Novartis (NVS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Merck (MRK) and Novartis (NVS)
MetricMRKNVS
Volatility (1Y, Annualized)29.83%26.99%
Beta (5Y)0.110.41
Max Drawdown (5Y)-43.44%-20.42%
Avg. Volume (3M)10.19M2.10M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
MRK and NVS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Merck (MRK) and Novartis (NVS)
MetricMRKNVS
Sharpe Ratio (1Y)1.980.77
Sortino Ratio (1Y)3.561.05

Profitability

ROE (TTM)

Novartis (NVS) at 24.33% sits in the top ROE quartile, while Merck (MRK) at 5.06% is closer to the peer norm — stronger capital efficiency for NVS.

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.06%

Max
109.18%
Q3
6.99%
MRK
5.06%
Median
-27.11%
Q1
-63.32%
Min
-153.84%

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.33%

Max
109.18%
NVS
24.33%
Q3
6.99%
Median
-27.11%
Q1
-63.32%
Min
-153.84%
Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Novartis (NVS) at 17.49% retains a top-quartile share of revenue as profit, ahead of Merck (MRK) at 3.64%, which keeps about the industry-typical share.

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.64%

Max
20.27%
Q3
4.98%
MRK
3.64%
Median
0.00%
Q1
-5.28%
Min
-18.66%

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.49%

Max
20.27%
NVS
17.49%
Q3
4.98%
Median
0.00%
Q1
-5.28%
Min
-18.66%
Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Merck (MRK) at 35.16% and Novartis (NVS) at 33.98% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.16%

Max
80.14%
MRK
35.16%
Q3
12.89%
Median
0.00%
Q1
-69.33%
Min
-189.53%

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.98%

Max
80.14%
NVS
33.98%
Q3
12.89%
Median
0.00%
Q1
-69.33%
Min
-189.53%
Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Merck (MRK) and Novartis (NVS)
MetricMRKNVS
ROE (TTM)5.06%24.33%
ROA (TTM)11.29%10.86%
Net Margin (TTM)3.64%17.49%
Operating Margin (TTM)35.16%33.98%
Gross Margin (TTM)75.20%75.21%

Growth

Revenue Growth

Both Merck (MRK) at 1.31% and Novartis (NVS) at 9.57% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Merck (MRK) at 8.01% and Novartis (NVS) at 21.81% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Merck (MRK) and Novartis (NVS)
MetricMRKNVS
Revenue Growth (YoY)1.31%9.57%
Revenue Growth (3Y CAGR)3.12%9.25%
EPS Growth (YoY)8.01%21.81%
EPS Growth (3Y CAGR)8.43%31.14%

Financial Strength

Current Ratio (MRQ)

Both Merck (MRK) at 1.35 and Novartis (NVS) at 0.88 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max
23.95
Q3
11.76
Median
5.04
Q1
2.44
MRK
1.35
Min
0.10

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.88

Max
23.95
Q3
11.76
Median
5.04
Q1
2.44
NVS
0.88
Min
0.10
Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Merck (MRK) at 1.20 and Novartis (NVS) at 1.29 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.20

Max
1.44
MRK
1.20
Q3
0.66
Median
0.15
Q1
0.02
Min
0.00

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.29

Max
1.44
NVS
1.29
Q3
0.66
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Merck (MRK) and Novartis (NVS)
MetricMRKNVS
Current Ratio (MRQ)1.350.88
Debt / Equity (MRQ)1.201.29
Net Debt / EBITDA1.501.64

Dividends

Dividend Yield (TTM)

Both Merck (MRK) at 2.29% and Novartis (NVS) at 2.91% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.29%

MRK
2.29%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.91%

NVS
2.91%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Merck (MRK) reports payout ratio above 100% at 343.43%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Novartis (NVS) reports 90.46%, ranking against industry peers normally.

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

343.43%

MRK
343.43%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

90.46%

NVS
90.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Merck (MRK) and Novartis (NVS)
MetricMRKNVS
Dividend Yield (TTM)2.29%2.91%
Dividend Payout Ratio (TTM)343.43%90.46%

Valuation

P/E Ratio (TTM)

Novartis (NVS) at 30.63 is near its industry’s usual P/E ratio, while Merck (MRK) at 149.25 sits above its peer range — an unusually expensive price for MRK’s trailing earnings.

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

149.25

MRK
149.25
Max
89.00
Q3
46.79
Median
27.68
Q1
14.13
Min
0.06

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.63

Max
89.00
Q3
46.79
NVS
30.63
Median
27.68
Q1
14.13
Min
0.06
Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Merck (MRK) at 5.41 and Novartis (NVS) at 5.28 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.41

Max
48.61
Q3
22.40
Median
6.95
MRK
5.41
Q1
3.09
Min
0.01

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max
48.61
Q3
22.40
Median
6.95
NVS
5.28
Q1
3.09
Min
0.01
Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both Merck (MRK) at 8.12 and Novartis (NVS) at 8.14 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.12

Max
13.20
MRK
8.12
Q3
6.63
Median
3.27
Q1
1.80
Min
-5.40

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.14

Max
13.20
NVS
8.14
Q3
6.63
Median
3.27
Q1
1.80
Min
-5.40
Loading chart…
Merck (MRK) vs. Novartis (NVS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Merck (MRK) and Novartis (NVS)
MetricMRKNVS
P/E Ratio (TTM)149.2530.63
P/S Ratio (TTM)5.415.28
P/B Ratio (MRQ)8.128.14
Free Cash Flow Yield (TTM)3.85%3.72%